Skip to main content
Cynthia Comella, MD, Neurology, Chicago, IL

Cynthia L Comella MD

Movement Disorder


Professor Emeritus Department of Neurological Sciences, Rush Medical College

Join to View Full Profile
  • 1725 W Harrison StSte 755Chicago, IL 60612

  • Phone+1 312-563-2900

  • Fax+1 312-563-2024

Dr. Comella is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Rush University Medical Center
    Rush University Medical CenterResidency, Neurology, 1985 - 1989
  • Rush University Medical Center
    Rush University Medical CenterResidency, Neurology, 1981 - 1984
  • Rush University Medical Center
    Rush University Medical CenterInternship, Internal Medicine, 1980 - 1981
  • University of Cincinnati College of Medicine
    University of Cincinnati College of MedicineClass of 1980

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 1983 - 2029
  • OH State Medical License
    OH State Medical License 2020 - 2028
  • Neurology
    American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012-2017
  • CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory EHR Suite, Epic Systems Corporation, 2012-2017
  • CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012-2017

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Acorda to Present Data for INBRIJA™ (Levodopa Inhalation Powder) at 2
    Acorda to Present Data for INBRIJA™ (Levodopa Inhalation Powder) at 2June 18th, 2018
  • Nuplazid’s Risks in Treating Parkinson’s Psychosis Don’t Appear Exceptionally High, Experts Say
    Nuplazid’s Risks in Treating Parkinson’s Psychosis Don’t Appear Exceptionally High, Experts SayJune 11th, 2018

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: